<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00036868</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-10995-16999</org_study_id>
    <secondary_id>EORTC-10995</secondary_id>
    <secondary_id>EORTC-16999</secondary_id>
    <secondary_id>IDBBC-EORTC-10995</secondary_id>
    <nct_id>NCT00036868</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy With Trastuzumab in Treating Women With Metastatic Breast Cancer</brief_title>
  <official_title>A Randomized Phase II Study Of CMF Alone And In Combination With Anti c-erbB2 Antibody (Herceptin) In Women With c-erbB2 Positive Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy such as cyclophosphamide, methotrexate, and&#xD;
      fluorouracil use different ways to stop tumor cells from dividing so they stop growing or&#xD;
      die. Monoclonal antibodies, such as trastuzumab, can locate tumor cells and either kill them&#xD;
      or deliver tumor-killing substances to them without harming normal cells. Combining&#xD;
      chemotherapy with trastuzumab may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of combining combination chemotherapy with&#xD;
      trastuzumab in treating women who have metastatic breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare the incidence of clinical heart failure in women with c-erbB2-positive&#xD;
           metastatic breast cancer treated with cyclophosphamide, methotrexate, and fluorouracil&#xD;
           in combination with trastuzumab (Herceptin®).&#xD;
&#xD;
        -  Compare the therapeutic activity of this regimen, in terms of objective response rate,&#xD;
           in these patients.&#xD;
&#xD;
        -  Compare the duration of response and time to progression in patients treated with this&#xD;
           regimen.&#xD;
&#xD;
        -  Compare the toxic effects of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive CMF comprising cyclophosphamide orally on days 1-14 or IV on days 1 and 8&#xD;
      and methotrexate IV and fluorouracil IV on days 1 and 8. Patients also receive trastuzumab&#xD;
      (Herceptin®) IV over 30-90 minutes once weekly beginning on day 1. Treatment repeats every 4&#xD;
      weeks for 8 courses. Patients then receive trastuzumab once every 3 weeks in the absence of&#xD;
      disease progression, unacceptable toxicity, or patient refusal.&#xD;
&#xD;
      Patients are followed every 8 weeks until documentation of disease progression or initiation&#xD;
      of a new anticancer therapy. Patients developing disease progression are followed every 12&#xD;
      weeks.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 66 patients will be accrued for this study within 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>February 2002</start_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical heart failure rate measured by New York Heart Association classification, LVEF, and ECG</measure>
    <time_frame>from registration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Response rate by RECIST</measure>
    <time_frame>from registration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of response by RECIST</measure>
    <time_frame>from registration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>from registration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity measured by CTC v2.0</measure>
    <time_frame>from registration</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>CMF + Herceptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>trastuzumab</intervention_name>
    <arm_group_label>CMF + Herceptin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CMF regimen</intervention_name>
    <arm_group_label>CMF + Herceptin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <arm_group_label>CMF + Herceptin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
    <arm_group_label>CMF + Herceptin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
    <arm_group_label>CMF + Herceptin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed metastatic breast cancer c-erbB2 positive (3+ overexpression&#xD;
             by the HercepTest™ method) in the primary tumor or metastatic site&#xD;
&#xD;
          -  At least 1 unidimensionally measurable target lesion&#xD;
&#xD;
               -  At least 20 mm by conventional techniques OR&#xD;
&#xD;
               -  At least 10 mm by spiral CT scan&#xD;
&#xD;
               -  Lesions that have been irradiated in the preceding 3 months cannot be used as&#xD;
                  target lesions unless they have appeared or clearly progressed since prior&#xD;
                  irradiation&#xD;
&#xD;
               -  No bone lesions as the only target lesions&#xD;
&#xD;
          -  No contralateral breast cancer that is c-erbB2-positive or c-erbB2-negative/unknown,&#xD;
             with status determined on a metastatic site&#xD;
&#xD;
          -  No CNS metastases&#xD;
&#xD;
               -  CT scan of brain and CSF cytology are required if neurologic symptoms are present&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Any estrogen or progesterone receptor status&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Sex:&#xD;
&#xD;
          -  Female&#xD;
&#xD;
        Menopausal status:&#xD;
&#xD;
          -  Any status&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 1.25 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Transaminases less than 2.5 times ULN (5 times ULN if liver metastases present)&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  For patients age 18 to 69:&#xD;
&#xD;
               -  Creatinine no greater than ULN&#xD;
&#xD;
          -  For patients age 70 and over:&#xD;
&#xD;
               -  Creatinine clearance normal&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  LVEF normal by MUGA or echocardiogram&#xD;
&#xD;
          -  No clinical heart failure&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  No malignancy-associated dyspnea at rest&#xD;
&#xD;
          -  No requirement for supportive oxygen therapy&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  No other prior or concurrent malignancy within the past 5 years except adequately&#xD;
             treated carcinoma in situ of the cervix or basal cell skin cancer&#xD;
&#xD;
          -  No psychological, familial, sociological, or geographical condition that would&#xD;
             preclude compliance with study therapy and follow-up schedule&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No prior anti-c-erbB2 antibody, including trastuzumab (Herceptin®)&#xD;
&#xD;
          -  No other concurrent biologic therapy&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No more than 1 prior chemotherapy regimen for metastatic breast cancer&#xD;
&#xD;
          -  Prior combination of cyclophosphamide, methotrexate, and fluorouracil (CMF) allowed in&#xD;
             the adjuvant or metastatic setting only if the disease-free interval after completion&#xD;
             of CMF was at least 12 months&#xD;
&#xD;
          -  Prior anthracyclines and/or taxanes allowed&#xD;
&#xD;
          -  At least 4 weeks since prior anthracyclines&#xD;
&#xD;
          -  No prior cumulative dose of doxorubicin more than 360 mg/m^2&#xD;
&#xD;
          -  No prior cumulative dose of epirubicin more than 720 mg/m^2&#xD;
&#xD;
          -  No prior cumulative dose of mitoxantrone more than 90 mg/m^2&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  More than 2 weeks since prior hormonal therapy in the adjuvant or metastatic setting&#xD;
&#xD;
          -  No concurrent hormonal therapy&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other concurrent anticancer therapy or investigational drugs&#xD;
&#xD;
          -  No concurrent bisphosphonates started after study enrollment except for hypercalcemia&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Cameron</last_name>
    <role>Study Chair</role>
    <affiliation>Western General Hospital, Edinburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ziekenhuis Netwerk Antwerpen Middelheim</name>
      <address>
        <city>Antwerp</city>
        <zip>2020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen</name>
      <address>
        <city>Edegem</city>
        <zip>B-2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herlev Hospital - University Hospital of Copenhagen</name>
      <address>
        <city>Copenhagen</city>
        <zip>DK-2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Institute of Egypt</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Lutte Contre le Cancer Georges-Francois Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onze Lieve Vrouwe Gasthuis</name>
      <address>
        <city>Amsterdam</city>
        <zip>1091 HA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <zip>2300 CA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nijmegen Cancer Center at Radboud University Medical Center</name>
      <address>
        <city>Nijmegen</city>
        <zip>NL-6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Gdansk</name>
      <address>
        <city>Gdansk</city>
        <zip>80-211</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Oncology and Radiology of Serbia</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Oncology Centre of Rosebank</name>
      <address>
        <city>Johannesburg</city>
        <zip>2193</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Infirmary</name>
      <address>
        <city>Glasgow</city>
        <state>Scotland</state>
        <zip>G11 6NT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>Egypt</country>
    <country>France</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Serbia</country>
    <country>South Africa</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Former Serbia and Montenegro</country>
  </removed_countries>
  <results_reference>
    <citation>Neskovic-Konstantinovic Z, Nooij M, Khaled H, et al.: Safety and efficacy of combined trastuzumab and CMF therapy in women with metastatic breast cancer: EORTC protocol 10995. [Abstract] J Clin Oncol 25 (Suppl 18): A-1040, 2007.</citation>
  </results_reference>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>May 13, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>June 6, 2013</last_update_submitted>
  <last_update_submitted_qc>June 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 7, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IV breast cancer</keyword>
  <keyword>recurrent breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

